Gland Pharma (GLAND) Q4 17/18 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 17/18 earnings summary
2 Nov, 2026Executive summary
FY18 gross income rose 9.6% YoY to Rs.16,716.82 Mn; profit after tax declined to Rs.3,211.14 Mn from Rs.4,137.26 Mn.
Fosun Pharma Industrial Pte. Ltd acquired 74% ownership in October 2017, followed by substantial changes to the board and senior leadership.
Financial highlights
Revenue from operations was Rs.16,228.93 Mn vs Rs.14,916.27 Mn; the periods are not comparable due to India’s GST transition from July 1, 2017.
Profit before tax was Rs.5,015.61 Mn vs Rs.5,780.11 Mn; profit after tax was Rs.3,211.14 Mn vs Rs.4,137.26 Mn.
Capital expenditure was Rs.494.07 Mn across manufacturing facilities; gross R&D expenditure was Rs.663.39 Mn vs Rs.600.76 Mn.
Outlook and guidance
New products were expected to launch in regulated markets during FY19, with additional ANDA filings planned; the stated priority was revenue and margin growth across existing and new markets.
R&D plans included developing processes for newer products and intermediates.
Latest events from Gland Pharma
- CDMO and U.S. growth lifted Q2 revenue 23% and PAT 58%.GLAND
Q2 26/27 - FY19 income grew 27.4%, led by exports, while ₹200 mn separation costs affected earnings.GLANDQ4 18/19
- FY20 export-led growth lifted revenue 28.81% and PAT 71.02%.GLANDQ4 19/20
- Revenue grew 32%, EBITDA margin reached 40%, and ROW revenue surged 136%.GLANDQ4 20/21
- Revenue grew 27% as capacity and product launches advanced despite cost and supply pressures.GLANDQ4 21/22
- FY23 earnings fell, while Cenexi expands European CDMO scale.GLANDQ4 22/23
- Revenue up 20% YoY, PAT up 47%, led by CDMO/B2B growth and strong US/Europe markets.GLANDQ1 26/27
- Q2 FY26 revenue up 6% YoY, PAT up 12%, led by US, Europe, and Cenexi growth.GLANDQ2 25/26
- Q3 FY25 revenue fell 10% YoY, but margins and new launches support future growth.GLANDQ3 24/25